Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,499 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult-Onset Diabetes Mellitus Clear all
Not listed Phase 3 Interventional

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

NCT01137695
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Pramlintide
Drug
Lead sponsor
Cheryl Rosenfeld, DO
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Denville, New Jersey • Staten Island, New York • Langhorne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2011 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Not applicable Interventional

Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications

NCT05166382
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Diseases
Interventions
Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D), Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 4, 2026, 2:59 AM EDT
Terminated Phase 4 Interventional Results available

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

NCT02072096
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glimepiride, Metformin, Pioglitazone, Acarbose, Linagliptin, Sitagliptin, Liraglutide, Insulin Glargine, Exenatide once weekly (QW), Exenatide twice daily (BID)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
65 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
Miami, Florida • New Port Richey, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Not applicable Interventional

Using Conversation Maps to Reinforce Self-Care

NCT00895986
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Conversation Maps Diabetes Education, Heart Healthy Living Diabetes Education
Behavioral
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
25 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Oct 4, 2026, 2:59 AM EDT
Terminated Phase 2 Interventional Results available

Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus

NCT02303405
View directory record Official record
Conditions
Diabetes Mellitus Type 2 With Hyperglycemia
Interventions
Hydroxychloroquine, Pioglitazone
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 2Phase 3 Interventional

Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes

NCT00143520
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Rivoglitazone, Pioglitazone, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
74
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 71 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT03219320
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
NYX-2925, Placebo
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Phoenix, Arizona • Anaheim, California • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 4, 2026, 2:59 AM EDT
Completed No phase listed Observational

TODAY2 Phase 2 Follow-up

NCT02310724
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
TODAY cohort
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

NCT01392573
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin degludec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
58
States / cities
Huntsville, Alabama • Vestavia Hills, Alabama • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Not applicable Interventional

Community-Based Diabetes Care for Korean American Immigrants

NCT01264796
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
culturally tailored diabetes education
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
30 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

NCT04865770
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Chronic Kidney Disease
Interventions
Semaglutide, Placebo (Semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • National City, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Alogliptin Pediatric Study

NCT02856113
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin Benzoate, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
10 Years to 17 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
34
States / cities
Little Rock, Arkansas • Los Angeles, California • Palmdale, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Not applicable Interventional

Bronx A1c: Bring it Down for Health

NCT00797888
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
telephonic
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 1 Interventional

Care Partner-Assisted Diabetes Self-Management Through Linking Continuous Glucose Monitoring With Mobile Health: Improving Outcomes for Older Adults With Mild Cognitive Impairment

NCT05601583
View directory record Official record
Conditions
Type 2 Diabetes, Mild Cognitive Impairment
Interventions
Continuous Glucose Monitor (CGM)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years to 100 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

NCT02065791
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Nephropathy
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years and older
Enrollment
4,401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
152
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)

NCT00542178
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Hypoglycemic Agents, Standard glycemia control, Intensive BP treatment, Standard BP control, Fenofibrate, Simvastatin, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
3,472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 4, 2026, 2:59 AM EDT
Terminated Phase 3 Interventional

GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes

NCT00229710
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Tesaglitazar
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

NCT02597049
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dulaglutide, Placebo, SGLT2 inhibitor, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
13
States / cities
Encino, California • Huntington Park, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 4, 2026, 2:59 AM EDT
Active, not recruiting Early Phase 1 Interventional

Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease

NCT06190158
View directory record Official record
Conditions
Type 2 Diabetes, Chronic Kidney Diseases
Interventions
Oral sodium suppression test, Saline suppression test, Captopril suppression test, Dexamethasone suppression test, Cosyntropin stimulation test
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Prevention of Weight Gain in Adult Patients With Type 2 Diabetes Treated With Pioglitazone

NCT00737347
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Lifestyle modification
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2008 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Not applicable Interventional

Diabetes Group Prenatal Care

NCT02444325
View directory record Official record
Conditions
Pregnancy, Gestational Diabetes, Type 2 Diabetes
Interventions
Group prenatal care
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Denver, Colorado • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 4, 2026, 2:59 AM EDT
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
204
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 4, 2026, 2:59 AM EDT
Completed Phase 2Phase 3 Interventional

Low Glycemic Load Diets in Latino Children at Risk for Type 2 Diabetes

NCT01068197
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus
Interventions
Low Glycemic Load Diet versus Low Fat Diet
Behavioral
Lead sponsor
Nazrat Mirza
Other
Eligibility
7 Years to 14 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 4, 2026, 2:59 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

NCT07784725
View directory record Official record
Conditions
Obesity or Overweight
Interventions
AZD6234, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
33
States / cities
Dothan, Alabama • Huntsville, Alabama • Mesa, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 4, 2026, 2:59 AM EDT